Ashish M. Kamat

机构：The University of Texas MD Anderson Cancer Center

发表论文 32 篇 · 总被引 1134 次 · h-index 13

代表论文

• A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer (2015 · European Urology · 被引 281)
• The Financial Burden of Localized and Metastatic Bladder Cancer (2024 · European Urology · 被引 74)
• Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group (2025 · European Urology · 被引 43)
• Reduced‐dose bacillus Calmette‐Guérin (BCG) in an era of BCG shortage: real‐world experience from a tertiary cancer centre (2021 · British Journal of Urology · 被引 19)
• Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non–muscle-invasive Bladder Cancer (2024 · European Urology Oncology · 被引 18)
• Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy (2021 · The Journal of Urology · 被引 18)